Elsilimomab (B-E8) is an anti-interleukin-6 (IL-6) monoclonal antibody. It is utilized in research on multiple myeloma and renal cell carcinoma to study its role in blocking IL-6-mediated signaling, which can inhibit mutant clone-induced stromal senescence in hematopoietic models, as explored in vitro.